217 related articles for article (PubMed ID: 34136421)
21. Effects of the combination of a monoclonal agonistic mouse anti-OX40 antibody and toll-like receptor agonists: Unmethylated CpG and LPS on an MB49 bladder cancer cell line in a mouse model.
Gulyás D; Kovács G; Jankovics I; Mészáros L; Lőrincz M; Dénes B
PLoS One; 2022; 17(7):e0270802. PubMed ID: 35802726
[TBL] [Abstract][Full Text] [Related]
22. Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy.
Sun Z; Chu Y; Xiao J; Yang Y; Meng F; Wang X; Dong Y; Zhu J; Wu Y; Qin L; Ke Y; Liu B; Liu Q
J Transl Med; 2023 Sep; 21(1):619. PubMed ID: 37700338
[TBL] [Abstract][Full Text] [Related]
23. Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma.
Chen L; Zhou S; Qin J; Hu H; Ma H; Liu B; Wang X; Ma J; Ye S; Zhong C; Zhou G; Liang C
Mol Cancer; 2013 Dec; 12(1):153. PubMed ID: 24304581
[TBL] [Abstract][Full Text] [Related]
24. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8
Peng W; Williams LJ; Xu C; Melendez B; McKenzie JA; Chen Y; Jackson HL; Voo KS; Mbofung RM; Leahey SE; Wang J; Lizee G; Tawbi HA; Davies MA; Hoos A; Smothers J; Srinivasan R; Paul EM; Yanamandra N; Hwu P
Clin Cancer Res; 2019 Nov; 25(21):6406-6416. PubMed ID: 31371342
[TBL] [Abstract][Full Text] [Related]
25. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
26. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma.
Reilley MJ; Morrow B; Ager CR; Liu A; Hong DS; Curran MA
J Immunother Cancer; 2019 Nov; 7(1):323. PubMed ID: 31771649
[TBL] [Abstract][Full Text] [Related]
27. Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma.
Deng Z; Teng YJ; Zhou Q; Ouyang ZG; Hu YX; Long HP; Hu MJ; Mei S; Lin FX; Dai XJ; Zhang BY; Feng T; Tian XF
World J Gastrointest Oncol; 2021 Nov; 13(11):1725-1740. PubMed ID: 34853646
[TBL] [Abstract][Full Text] [Related]
28. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
[TBL] [Abstract][Full Text] [Related]
29. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
Redmond WL; Triplett T; Floyd K; Weinberg AD
PLoS One; 2012; 7(4):e34467. PubMed ID: 22496812
[TBL] [Abstract][Full Text] [Related]
30. Eradication of spontaneous malignancy by local immunotherapy.
Sagiv-Barfi I; Czerwinski DK; Levy S; Alam IS; Mayer AT; Gambhir SS; Levy R
Sci Transl Med; 2018 Jan; 10(426):. PubMed ID: 29386357
[TBL] [Abstract][Full Text] [Related]
31. Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma.
Zhou B; Yan J; Guo L; Zhang B; Liu S; Yu M; Chen Z; Zhang K; Zhang W; Li X; Xu Y; Xiao Y; Zhou J; Fan J; Hung MC; Li H; Ye Q
Theranostics; 2020; 10(14):6530-6543. PubMed ID: 32483468
[TBL] [Abstract][Full Text] [Related]
32. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases.
Pan PY; Zang Y; Weber K; Meseck ML; Chen SH
Mol Ther; 2002 Oct; 6(4):528-36. PubMed ID: 12377195
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer.
Hong WX; Sagiv-Barfi I; Czerwinski DK; Sallets A; Levy R
Cancer Res; 2022 Apr; 82(7):1396-1408. PubMed ID: 35135810
[TBL] [Abstract][Full Text] [Related]
34. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.
Jacobs C; Duewell P; Heckelsmiller K; Wei J; Bauernfeind F; Ellermeier J; Kisser U; Bauer CA; Dauer M; Eigler A; Maraskovsky E; Endres S; Schnurr M
Int J Cancer; 2011 Feb; 128(4):897-907. PubMed ID: 20473889
[TBL] [Abstract][Full Text] [Related]
35. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
36. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma.
Voo KS; Foglietta M; Percivalle E; Chu F; Nattamai D; Harline M; Lee ST; Bover L; Lin HY; Baladandayuthapani V; Delgado D; Luong A; Davis RE; Kwak LW; Liu YJ; Neelapu SS
Int J Cancer; 2014 Dec; 135(12):2834-46. PubMed ID: 24771328
[TBL] [Abstract][Full Text] [Related]
37. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
38. Early Therapeutic Vaccination Prediction of Hepatocellular Carcinoma via Imaging OX40-Mediated Tumor Infiltrating Lymphocytes.
Chen X; Li D; Cao Y; Gao J; Jin H; Shan H
Mol Pharm; 2019 Oct; 16(10):4252-4259. PubMed ID: 31454248
[TBL] [Abstract][Full Text] [Related]
39. CXCR2 inhibition enables NASH-HCC immunotherapy.
Leslie J; Mackey JBG; Jamieson T; Ramon-Gil E; Drake TM; Fercoq F; Clark W; Gilroy K; Hedley A; Nixon C; Luli S; Laszczewska M; Pinyol R; Esteban-Fabró R; Willoughby CE; Haber PK; Andreu-Oller C; Rahbari M; Fan C; Pfister D; Raman S; Wilson N; Müller M; Collins A; Geh D; Fuller A; McDonald D; Hulme G; Filby A; Cortes-Lavaud X; Mohamed NE; Ford CA; Raffo Iraolagoitia XL; McFarlane AJ; McCain MV; Ridgway RA; Roberts EW; Barry ST; Graham GJ; Heikenwälder M; Reeves HL; Llovet JM; Carlin LM; Bird TG; Sansom OJ; Mann DA
Gut; 2022 Apr; 71(10):2093-106. PubMed ID: 35477863
[TBL] [Abstract][Full Text] [Related]
40. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
